* Meta-terms correspond to biological or medical specialty concerned with one or more keywords (or keywords hierarchies), qualifiers, or resource types. Other terms also benefit from this structure, when the topic warrants it, eg education. See the list.

Doc'CISMeF search for this specility :


Preferred Label : hematology;

True Meta (CISMeF) : O;

Details


Main resources

You can consult :


https://ansm.sante.fr/tableau-marr/eculizumab-2
2024
false
false
false
France
French
risk management
eculizumab
eculizumab
eculizumab
guidelines for drug use
patient education handout
patients guideline
antibiotic prophylaxis
infusions, intravenous
Infections
sepsis
Drug-Related side effects and adverse reactions
meningococcal infections
vaccination
meningococcal vaccines

---
https://ansm.sante.fr/tableau-marr/thalidomide
2024
false
false
false
France
French
risk management
thalidomide
teratogens
abnormalities, drug-induced
pregnancy
thalidomide
guideline
forms
patient education handout
continuity of patient care
Neuropathy peripheral
thromboembolism
Drug-Related side effects and adverse reactions
pregnancy tests
contraception
package leaflet

---
https://www.has-sante.fr/jcms/p_3486120/fr/tibsovo-ivosidenib-cancer-des-voies-biliaires
2024
false
false
false
France
locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation
adult
treatment outcome
insurance, health, reimbursement
cholangiocarcinoma
Locally Advanced Cholangiocarcinoma
Metastatic Cholangiocarcinoma
administration, oral
antineoplastic agents
ivosidenib
evaluation of the transparency committee
ivosidenib

---
https://www.has-sante.fr/jcms/p_3478093/fr/blincyto-blinatumomab-lal-en-echec-d-au-moins-2-traitements-avec-itk
2024
false
false
false
France
precursor cell lymphoblastic Leukemia-Lymphoma
leukemia, lymphocytic, acute, L2
B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1
antineoplastic agents
blinatumomab
evaluation of the transparency committee
blinatumomab

---
https://www.has-sante.fr/jcms/p_3488284/fr/caspofungine-tillomed-caspofungine-antimycotique-a-usage-systemique
2024
false
false
false
France
drugs, generic
infusions, intravenous
caspofungin
evaluation of the transparency committee
Caspofungin
antifungal agents

---
https://www.has-sante.fr/jcms/p_3488174/fr/nplate-romiplostim-thrombopenie-immunologique-primaire-pti-refractaire-aux-autres-traitements
2024
false
false
false
France
Primary Immune Thrombocytopenia
evaluation of the transparency committee
nplate
principal
Romiplostim
Immunotherapy
romiplostim
Refractory
thrombocytopenia due to immune destruction, nos
Primary Refractory
romiplostim
idiopathic thrombocytopenic purpura, nos
Other Therapy
Immune
Immunology
thrombocytopenia
purpura, thrombocytopenic, idiopathic
immunology

---
https://ansm.sante.fr/tableau-marr/susoctocog-alfa
2024
false
false
false
France
French
risk management
Susoctocog Alfa
medication errors
guidelines for drug use
drug dosage calculations
video recording

---
https://www.has-sante.fr/jcms/p_3490841/fr/reblozyl-luspatercept-anemie-associee-a-une-beta-thalassemie
2024
false
false
false
France
evaluation of the transparency committee
beta-Thalassemia
luspatercept

---
https://ansm.sante.fr/tableau-marr/mecasermine
2024
false
false
false
France
French
risk management
mecasermin
mecasermin
mecasermin
Drug-Related side effects and adverse reactions
patient education handout
guidelines for drug use
mecasermin
hypoglycemia
injections, subcutaneous

---
https://www.canada.ca/fr/sante-publique/services/maladies-infectieuses/sante-sexuelle-infections-transmissibles-sexuellement/lignes-directrices-canadiennes/guide-prevention-itss.html
2024
Canada
guideline
public health guidelines
Blood Sample
Prevention Study
Guide Device
infectious disease, nos
Prevention
Murine Blood
Sexually Transmitted Disorder
Preventive Intervention
Handbook
Blood
infection control
blood
sexually transmitted diseases

---
https://ansm.sante.fr/actualites/decision-du-13-02-2024-cadre-de-prescription-compassionnelle-de-tibsovo-ivosidenib-250mg-comprime-pellicule
https://ansm.sante.fr/tableau-acces-derogatoire/ivosidenib
2024
false
false
false
France
French
drug information
administration, oral
ivosidenib
adult
glioma
guidelines for drug use
continuity of patient care
Unresectable Low Grade Glioma
Refractory Low Grade Glioma
IDH1 Gene Mutation
ivosidenib

---
https://www.has-sante.fr/jcms/p_3497026/fr/mircera-methoxy-polyethylene-glycol-epoetine-beta-anemie-symptomatique-associee-a-l-insuffisance-renale-chronique-chez-les-enfants-ages-de-3-mois-a-moins-de-18-ans
2024
false
false
false
France
infant
adolescent
treatment outcome
insurance, health, reimbursement
hematinics
methoxy polyethylene glycol-epoetin beta
Anemia of chronic renal failure (disorder)
evaluation of the transparency committee
continuous erythropoietin receptor activator
polyethylene glycols
anemia
erythropoietin
methoxy polyethylene glycol-epoetin beta
renal insufficiency, chronic
child

---
https://www.cochrane.org/fr/CD011858/RENAL_traitements-pour-fluidifier-le-sang-pendant-lhemodialyse-quels-sont-les-traitements-qui-reduisent
2024
United Kingdom
review of literature
french abstract
Issue
Hemorrhage
blood
problem, nos
Blood Sample
evoked
Dexamethasone
hemodialysis
Coagulation Process
hemorrhage, nos
hemodialysis, nos
hemorrhage
coagulants
renal dialysis
Hemodialysis
Blood
coagulant, nos
Murine Blood
Biggest Problem
What Month is it
Adverse Event Associated with Coagulation

---
https://www.has-sante.fr/jcms/p_3498568/fr/lovenox-enoxaparine-sodique-traitement-antithrombotique
2024
false
false
false
France
evaluation of the transparency committee
enoxaparin
antithrombotic agents
Treat
During Treatment
No Treatment for Diabetes
Therapy Object
fibrinolytic agents
Treatment Epoch
Treatment
Biomaterial Treatment
On Treatment
Thrombolytic Agent
GDC Treatment Frequency Terminology
Treatment Study
Enoxaparin Sodium
lovenox

---
https://www.has-sante.fr/jcms/p_3498750/fr/keytruda-pembrolizumab-carcinome-a-cellules-renales
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
adult
antineoplastic combined chemotherapy protocols
clear cell renal cell carcinoma
Lenvatinib/Pembrolizumab Regimen
Advanced Clear Cell Renal Cell Carcinoma
infusions, intravenous
Antineoplastic Agents, Immunological
pembrolizumab
evaluation of the transparency committee
pembrolizumab
carcinoma, renal cell

---
https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/protocole-medical-national-initier-un-test-immunochimique-de-recherche-de-sang-occulte-dans-les-selles-ou-une-coloscopie-a-des-fins-de-depistage-ou-de-diagnostic-du-cancer-colorectal.html
2024
Canada
public health guidelines
Test Name
immunochemistry
colonoscopy
On Study
screening for cancer
dermatomyositis
Colorectal Cancer
Cancer Diagnosis
biomedical research
Laboratory Procedure
Screening Colonoscopy
Test Dosing Unit
Screening for Colorectal Cancer
cancer screening
malignant neoplasm colon/rectum
early detection of cancer
Initiation
diagnosis
no diagnosis
Fecal Occult Blood Test
Blood Products Laboratory Testing
feces
screening for occult blood in feces
Clinical Study Protocol
medical research
colorectal neoplasms
occult blood

---
https://minerva-ebp.be/Theme/Analysis/855
2024
Belgium
critical appraisal or critical reading
pulmonary embolism
guideline
anticoagulants
anticoagulotherapy
leadership
Anticoagulation Therapy
Update
anticoagulant, nos
Pulmonary Embolism
Direct Oral Anticoagulant
pulmonary embolism
Long-Term
pulmonary embolism
oral anticoagulants
Software Maintenance

---
https://www.has-sante.fr/jcms/p_3501630/fr/tepkinly-epcoritamab-lymphome-diffus-a-grande-cellule-b-ldgcb
2024
France
evaluation of the transparency committee
Murine Large Cell
Gastric Diffuse Adenocarcinoma
lymphoma, diffuse
B-Lymphocyte
lymphoma, large B-Cell, diffuse
Epcoritamab
b-lymphocytes
b lymphocyte
malignant lymphoma, nos
Childhood Lymphoma
Murine B-Lymphocytes
cells
Adult Lymphoma

---
https://www.cochrane.org/fr/CD013293/RENAL_quelle-est-la-meilleure-methode-pour-sauver-un-acces-dhemodialyse-coagule
2024
United Kingdom
review of literature
french abstract
coagulant, nos
Hemodialysis
Test Method
protestantism
coagulants
hemodialysis
What Month is it
CDISC SDTM Method Terminology
Clotted Specimen
Methodology
renal dialysis
hemodialysis, nos
Technique
Dexamethasone

---
https://sfar.org/gestion-de-lanticoagulation-dans-un-contexte-durgence/
2024
France
guideline
algorithms
anticoagulants
Application Context
emergencies
anticoagulant, nos
Anticoagulant Agent
Contingency Management

---
https://sfar.org/optimisation-hemodynamique-perioperatoire-adulte-dont-obstetrique/
2024
France
guideline
Optimization
obstetrics
hemodynamics
Perioperative
Observational Study Sampling Method

---
https://sfar.org/optimisation-hemodynamique-perioperatoire-pediatrie/
2024
France
guideline
Perioperative
pediatrics
hemodynamics
Pediatric
pediatrician
Optimization
Pediatric

---
https://www.cochrane.org/fr/CD014544/CF_quels-sont-les-benefices-et-les-risques-des-nouveaux-traitements-par-facteurs-non-coagulants-pour-la
2024
United Kingdom
review of literature
french abstract
risk factors
blood coagulation factors
hemophilia B
bloodletting
coagulants
Treatment Benefit
Feeding
Breeding
Risk Factor
Coagulation Factor
hemophilia b, nos
persons
risks and benefits
risk factor
F9 wt Allele
Feeding Ability
Prevention Study
Hemophilia B
What Month is it
disease
Raw
coagulation factor, nos
Hemorrhage
Preventive Intervention
risk assessment
bleeding precautions
hemorrhage
People
New Lesion Identification
Newar Language
preventive treatment, nos

---
https://ansm.sante.fr/actualites/avis-de-lansm-du-11-03-2024-sur-le-medicament-keytruda-dans-le-cadre-dune-demande-daap
2024
false
false
false
France
French
treatment outcome
pembrolizumab
Antineoplastic Agents, Immunological
drug information
Resectable Lung Non-Small Cell Carcinoma
carcinoma, non-small-cell lung
neoplasm recurrence, local
risk
pembrolizumab

---
https://ansm.sante.fr/tableau-marr/sutimlimab
2024
false
false
false
France
French
risk management
sutimlimab
guidelines for drug use
sutimlimab
antibodies, monoclonal, humanized
infusions, intravenous
Infections
Infections
meningococcal vaccines
meningococcal infections
vaccination
serious infection
patient education handout

---
https://ansm.sante.fr/tableau-acces-derogatoire/blenrep
2024
false
false
false
France
French
infusions, intravenous
drug information
antibodies, monoclonal, humanized
belantamab mafodotin
Antineoplastic Agents, Immunological

---
https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/equivalence-du-seuil-de-positivite-des-tests-immunochimiques-de-recherche-de-sang-occulte-dans-les-selles-pour-le-depistage-du-cancer-colorectal.html
2024
Canada
review of literature
feces
early detection of cancer
Equivalent
screening for occult blood in feces
cancer screening
screening for cancer
Research
Search
research
immunochemistry
Blood in Stool
colorectal neoplasms
Occult Blood Measurement
Colorectal Cancer
Screening for Colorectal Cancer
occult blood
Liquid Tumor
malignant neoplasm colon/rectum

---
https://ansm.sante.fr/tableau-marr/crizotinib
2024
false
false
false
France
French
patients guideline
patient education handout
drug information
risk management
Crizotinib
Crizotinib
continuity of patient care
crizotinib
vision disorders
adult
child

---
https://ansm.sante.fr/tableau-marr/teclistamab
2024
false
false
false
France
French
popular works
drug information
Teclistamab
risk management
teclistamab

---
https://ansm.sante.fr/tableau-acces-derogatoire/tecartus-0-4-2-x-108-cellules-dispersion-pour-perfusion
2024
false
false
false
France
French
brexucabtagene autoleucel
drug information
Refractory B Acute Lymphoblastic Leukemia
precursor cell lymphoblastic Leukemia-Lymphoma
brexucabtagene autoleucel
gene therapy

---
https://ansm.sante.fr/tableau-acces-derogatoire/ivosidenib
2024
false
false
false
France
French
administration, oral
summary of product characteristics
cholangiocarcinoma
guidelines for drug use
leukemia, myeloid, acute
glioma
myelodysplastic syndromes
antineoplastic agents
ivosidenib
ivosidenib
neoplasm metastasis
package leaflet

---
https://ansm.sante.fr/tableau-acces-derogatoire/keytruda-25-mg-ml-solution-a-diluer-pour-perfusion#
2024
false
false
false
France
French
drug information
triple negative breast neoplasms
pembrolizumab
pembrolizumab
summary of product characteristics
package leaflet
guidelines for drug use
adult
Early Stage Triple-Negative Breast Carcinoma
Locally Advanced Triple-Negative Breast Carcinoma
inflammatory breast neoplasms
Antineoplastic Agents, Immunological
endometrial neoplasms
clear cell renal cell carcinoma
renal cell carcinoma at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions

---
https://ansm.sante.fr/tableau-marr/panobinostat
2024
false
false
false
France
French
risk management
Panobinostat
panobinostat
administration, oral
medication errors
patients guideline
patient compliance

---
https://ansm.sante.fr/tableau-marr/icodextrine
2024
false
false
false
France
French
risk management
guidelines for drug use
peritoneal dialysis
blood glucose self-monitoring
Icodextrin

---
https://hemato.chu-limoges.fr/
false
false
false
false
France
French
popular works
teaching structure
research structure
hematologic diseases
hematology

---
https://ansm.sante.fr/tableau-acces-derogatoire/yescarta-0-4-2-x-108-cellules-dispersion-pour-perfusion#
2024
false
false
false
France
French
axicabtagene ciloleucel
axicabtagene ciloleucel
biological products
Antineoplastic Agents, Immunological
Recurrent High Grade B-Cell Lymphoma
lymphoma, large B-Cell, diffuse
adult
Refractory High Grade B-Cell Lymphoma
drug information
immunotherapy, adoptive
antigens, CD19

---
https://ansm.sante.fr/tableau-marr/lenalidomide
2024
false
false
false
France
French
risk management
pregnancy
contraception
lenalidomide
multiple myeloma
lymphoma, mantle-cell
teratogens
continuity of patient care
drug monitoring
clinical chemistry tests
myelodysplastic syndromes
guidelines for drug use
popular works
venous thromboembolism
Tumor Flare Reaction
neoplasms
Chemical and Drug Induced Liver Injury
angiogenesis inhibitors
angiogenesis inhibitors
thalidomide
thalidomide
thalidomide
Lenalidomide
Lenalidomide

---
https://ansm.sante.fr/tableau-marr/pomalidomide
2024
false
false
false
France
French
risk management
pregnancy
contraception
teratogens
abnormalities, drug-induced
multiple myeloma
pomalidomide
continuity of patient care
Drug-Related side effects and adverse reactions
risk factors
guidelines for drug use
thrombocytopenia
neutropenia
blood cell count
thromboembolism
Infections
patient education handout
pregnancy tests
forms
thalidomide
thalidomide

---
https://ansm.sante.fr/actualites/hemovigilance-lansm-fait-evoluer-la-declaration-des-effets-indesirables-donneurs-de-sang
2024
false
false
false
France
French
scientific and technical information
blood safety
hemovigilance
blood donors
reports of adverse events
france

---
https://www.has-sante.fr/jcms/p_3442461/fr/xalkori-crizotinib-tumeurs-myofibroblastiques-inflammatoires-tmi
2023
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
Crizotinib
crizotinib
Inflammatory Myofibroblastic Tumor
antineoplastic agents
protein kinase inhibitors
child
adolescent
Childhood Inflammatory Myofibroblastic Tumor
soft tissue neoplasms
ALK Positive
administration, oral

---
https://pap-pediatrie.fr/immuno-infectio-parasito/splenomegalie-chez-lenfant
2023
France
algorithms
Child
splenomegaly, nos
child
Splenomegaly
Child
Child
splenomegaly
splenomegaly
Child
child, nos

---
https://www.minerva-ebp.be/FR/Article/2323
2023
Belgium
critical appraisal or critical reading
aspirin
anticoagulant, nos
cardiovascular prevention
principal
role
primary prevention
anticoagulants
systolic pressure
acetylsalicylic acid

---
https://www.has-sante.fr/jcms/p_3443949/fr/hemlibra-emicizumab-hemophilie-a
2023
false
false
false
France
emicizumab
treatment outcome
insurance, health, reimbursement
hemorrhage
guidelines for drug use
evaluation of the transparency committee
hemophilia A
emicizumab

---
https://www.ema.europa.eu/en/medicines/human/EPAR/enjaymo
2023
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
sutimlimab
sutimlimab
sutimlimab
orphan drug production
cold agglutinin disease
anemia, hemolytic, autoimmune
adult
infusions, intravenous
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical

---
https://www.ema.europa.eu/en/medicines/human/EPAR/epysqli
2023
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
eculizumab
eculizumab
eculizumab
biosimilar pharmaceuticals
hemoglobinuria, paroxysmal
adult
child
pregnancy
breast feeding
drug interactions
product surveillance, postmarketing
infusions, intravenous
drug evaluation, preclinical

---
https://www.ema.europa.eu/en/medicines/human/EPAR/tibsovo-0
2023
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
ivosidenib
ivosidenib
ivosidenib
orphan drug production
antineoplastic agents
antineoplastic agents
adult
enzyme inhibitors
enzyme inhibitors
antineoplastic combined chemotherapy protocols
Azacitidine/Ivosidenib Regimen
leukemia, myeloid, acute
IDH1 NP_005887.2:p.R132X
leukemia, myeloid, acute
IDH1 Gene Mutation
cholangiocarcinoma
Locally Advanced Cholangiocarcinoma
Metastatic Cholangiocarcinoma
cholangiocarcinoma
mutation
administration, oral
IDH1 protein, human
IDH1 inhibitor
product surveillance, postmarketing
drug interactions
fertility
pregnancy
breast feeding
drug evaluation, preclinical
acute myeloid leukaemia with an IDH1 R132 mutation
locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation

---
https://www.has-sante.fr/jcms/p_3444785/fr/xalkori-crizotinib-lymphome-anaplasique-a-grandes-cellules-lagc
2023
false
false
false
France
French
treatment outcome
child
insurance, health, reimbursement
administration, oral
Crizotinib
crizotinib
evaluation of the transparency committee
adolescent
Refractory Systemic Anaplastic Large Cell Lymphoma, ALK-Positive
Recurrent Systemic Anaplastic Large Cell Lymphoma, ALK-Positive
antineoplastic agents
protein kinase inhibitors
lymphoma, large-cell, anaplastic

---
https://ansm.sante.fr/informations-de-securite/adakveo-crizanlizumab-retrait-de-lautorisation-de-mise-sur-le-marche-en-raison-dun-manque-defficacite
2023
false
false
false
France
French
drug information
Drug effect lack of
crizanlizumab
crizanlizumab
anemia, sickle cell
Vaso-Occlusive Crisis
Safety-Based drug withdrawals

---
https://www.has-sante.fr/jcms/p_3448025/fr/oxbryta-voxelotor-anemie-hemolytique
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
voxelotor
hematologic agents
anemia, sickle cell
adult
adolescent
summary of product characteristics
drug therapy, combination
evaluation of the transparency committee
voxelotor
anemia, hemolytic

---
https://www.has-sante.fr/jcms/p_3396878/fr/keytruda-pembrolizumab-cancer-du-sein-triple-negatif
2023
false
false
false
France
triple negative breast neoplasms
treatment outcome
insurance, health, reimbursement
Antineoplastic Agents, Immunological
pembrolizumab
antineoplastic combined chemotherapy protocols
infusions, intravenous
Locally Advanced Triple-Negative Breast Carcinoma
Early Stage Triple-Negative Breast Carcinoma
locally advanced triple negative breast cancer at high risk of recurrence
early stage triple negative breast cancer at high risk of recurrence
evaluation of the transparency committee
pembrolizumab

---
https://www.has-sante.fr/jcms/p_3409403/fr/keytruda-pembrolizumab-carcinome-a-cellule-renale
2023
false
false
false
France
chemotherapy, adjuvant
treatment outcome
insurance, health, reimbursement
pembrolizumab
infusions, intravenous
Antineoplastic Agents, Immunological
clear cell renal cell carcinoma
nephrectomy
clear cell renal cell carcinoma
renal cell carcinoma at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions
evaluation of the transparency committee
pembrolizumab
carcinoma, renal cell

---
https://www.has-sante.fr/jcms/p_3445722/fr/gabarit-mammaire-gonflable
2023
France
health technology assessment
anatomists
breast, nos
serum
with texture
serum
physiologist
Anatomy
anatomy
anatomist
Anatomy
physiology
microscopy

---
https://www.has-sante.fr/jcms/p_3445728/fr/gabarit-mammaire-gonflable
2023
France
health technology assessment
microscopy
serum
anatomist
breast, nos
anatomists
Anatomy
physiologist
serum
Anatomy
with texture
anatomy
physiology

---
https://www.has-sante.fr/jcms/p_3447489/fr/ebvallo-tabelecleucel-hemopathie-maligne
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
Tabelecleucel
Adoptive Cell Therapy Agent
adult
child
adolescent
EBV-Related Post-Transplant Lymphoproliferative Disorder
Refractory Neoplastic Post-Transplant Lymphoproliferative Disorder
Recurrent Neoplastic Post-Transplant Lymphoproliferative Disorder
tabelecleucel
evaluation of the transparency committee
Malignant hemopathy
hematologic neoplasms

---
https://ansm.sante.fr/tableau-acces-derogatoire/ebvallo
2023
false
false
false
France
French
drug information
Tabelecleucel

---
https://www.has-sante.fr/jcms/p_3447364/fr/hemlibra-emicizumab-hemophilie-a-deficit-congenital-en-facteur-viii
2023
false
false
false
France
French
insurance, health, reimbursement
treatment outcome
emicizumab
hemophilia A
hemorrhage
emicizumab
evaluation of the transparency committee

---
http://oncologik.fr/referentiels/sforl/adenopathies-metastatiques-de-carcinome-epidermoide-sans-porte-d-entree
2023
France
guideline
Squamous cell carcinoma
enlargement of lymph nodes, nos
carcinoma, squamous cell
Lymphadenopathy
Adenopathy
squamous cell carcinoma, metastatic, nos
entrance

---
https://creaiors-occitanie.fr/wp-content/uploads/2023/06/CREAI-ORS_synthese-EPS-PA-2022_FIN_20230525.pdf
2023
France
scientific and technical information
elderly person, nos
exophthalmos producing substance
equipment
health
health education
health facility size
aged, 80 and over
aged
blood protein electrophoresis
gatekeeping

---
https://cps.ca/fr/documents/position/la-prise-en-charge-de-la-neutropenie-febrile-chez-les-enfants-et-les-adolescents-immunocompetents
2023
Canada
practice guideline
patient care management
Adolescent
increased body temperature
child
febrile neutropenia
Child
Child
adolescent
neutropenia, nos
Neutropenia
Adolescent
Child
child, nos
Child
adolescence

---
https://www.has-sante.fr/jcms/p_3448231/fr/calquence-acalabrutinib-leucemie-lymphoide-chronique-llc
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
administration, oral
tablets
antineoplastic agents
protein kinase inhibitors
acalabrutinib
Acalabrutinib/Obinutuzumab Regimen
evaluation of the transparency committee
leukemia, lymphocytic, chronic, B-Cell
Chronic lymphocytic leukemia
acalabrutinib

---
https://ansm.sante.fr/tableau-acces-derogatoire/ayvakyt
2023
false
false
false
France
French
administration, oral
avapritinib
avapritinib
drug information
aggressive systemic mastocytosis
mastocytosis, systemic
Systemic Mastocytosis with an Associated Myeloid Neoplasm
leukemia, mast-cell
adult

---
https://www.cnear.fr/_files/ugd/361ef2_f729ae1a6c69473897aa393767397cb8.pdf
2023
false
false
false
France
educational course
French pre-residency program examination
shunt, nos
blood transfusion
Transfusions
blood
transfusion, nos

---
https://www.has-sante.fr/jcms/p_3451606/fr/kymriah-tisagenlecleucel-lymphome-folliculaire
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
tisagenlecleucel
tisagenlecleucel
lymphoma, follicular
Recurrent Follicular Lymphoma
Refractory Follicular Lymphoma
evaluation of the transparency committee

---
https://www.has-sante.fr/jcms/p_3451087/fr/ebvallo-tabelecleucel-hemopathie-maligne
2023
false
false
false
France
French
evaluation of the transparency committee
Tabelecleucel

---
https://www.has-sante.fr/jcms/p_3454298/fr/brukinsa-zanubrutinib-lymphome-de-la-zone-marginale-lzm
2023
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
zanubrutinib
zanubrutinib
administration, oral
adult
Recurrent Marginal Zone Lymphoma
antineoplastic agents
protein kinase inhibitors

---
https://www.has-sante.fr/jcms/p_3455563/fr/ultomiris-ravulizumab-myasthenie-acquise-generalisee
2023
false
false
false
France
French
treatment outcome
insurance, health, reimbursement
evaluation of the transparency committee
ravulizumab
ravulizumab
myasthenia gravis, generalized
adult

---
https://www.cochrane.org/fr/CD015078/HAEMATOL_les-agents-antiplaquettaires-sont-ils-un-traitement-efficace-chez-les-personnes-atteintes-de-la
2023
United Kingdom
review of literature
french abstract
antiplatelet agents
persons
disease
platelet aggregation inhibitors
COVID-19

---
https://www.has-sante.fr/jcms/p_3456306/fr/novoseven-eptacog-alfa-active-hemorragies-du-post-partum-severes
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
coagulation factor VIIa
recombinant FVIIa
injections, intravenous
evaluation of the transparency committee
eptacog alfa
postpartum hemorrhage

---
https://www.has-sante.fr/jcms/p_3456309/fr/xenpozyme-olipudase-alfa-maladie-rare
2023
false
false
false
France
infusions, intravenous
treatment outcome
insurance, health, reimbursement
olipudase alfa
enzyme replacement therapy
child
adult
orphan drug production
Acid sphingomyelinase deficiency
niemann-pick diseases
evaluation of the transparency committee
rare diseases
olipudase alfa

---
https://www.has-sante.fr/jcms/p_3456312/fr/ceprotin-proteine-c-humaine-deficit-congenital-severe-en-proteine-c
2023
false
false
false
France
protein C
treatment outcome
insurance, health, reimbursement
protein c
protein c deficiency
Coumarin necrosis (disorder)
purpura fulminans
venous thrombosis
evaluation of the transparency committee
protein c deficiency

---
https://www.has-sante.fr/jcms/p_3456902/fr/ultomiris-ravulizumab-neuromyelite-optique
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
ravulizumab
Product containing only ravulizumab in parenteral dose form (medicinal product form)
infusions, intravenous
adult
neuromyelitis optica spectrum disorders who are anti-aquaporin 4 antibody positive
Neuromyelitis optica spectrum disorder with anti-AQP4 antibodies
evaluation of the transparency committee
neuromyelitis optica
ravulizumab

---
https://publications.msss.gouv.qc.ca/msss/document-003620/
2023
Canada
popular works
family, nos
Child
Child
child, nos
anemia, sickle cell
family
anemia
drepanocyte
Handbook
Child
Child
anemia, nos
child care
Anemia

---
https://ansm.sante.fr/tableau-acces-derogatoire/scemblix-20-mg-40-mg-comprimes-pellicules
2023
false
false
false
France
French
asciminib
administration, oral
guidelines for drug use
asciminib
protein kinase inhibitors
summary of product characteristics
package leaflet
leukemia, lymphocytic, acute, L2
leukemia, lymphocytic, acute, L2
mutation
T315I mutation
leukemia, myelogenous, chronic, bcr-abl positive
leukemia, myelogenous, chronic, bcr-abl positive

---
https://ansm.sante.fr/tableau-acces-derogatoire/breyanzi
2023
false
false
false
France
French
Lisocabtagene Maraleucel
Product containing only lisocabtagene maraleucel in parenteral dose form (medicinal product form)
summary of product characteristics
package leaflet
guidelines for drug use
lymphoma, large B-Cell, diffuse
adult
Recurrent High Grade B-Cell Lymphoma
Refractory High Grade B-Cell Lymphoma
Recurrent Primary Mediastinal Large B-Cell Lymphoma
Refractory Primary Mediastinal Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
infusions, intravenous
continuity of patient care
immunotherapy, adoptive
antigens, CD19
lisocabtagene maraleucel

---
https://ansm.sante.fr/tableau-acces-derogatoire/teclistamab
2023
false
false
false
France
French
drug information
Teclistamab
adult
multiple myeloma
Recurrent Multiple Myeloma
Refractory Multiple Myeloma
summary of product characteristics
package leaflet
antibodies, monoclonal
Antineoplastic Agents, Immunological
teclistamab

---
https://ansm.sante.fr/tableau-acces-derogatoire/xenpozyme#
2023
false
false
false
France
French
drug information
olipudase alfa
olipudase alfa
enzyme replacement therapy
child
adolescent
adult
niemann-pick diseases

---
https://ansm.sante.fr/tableau-marr/ciltacabtagene-autoleucel
2023
false
false
false
France
French
risk management
guidelines for drug use
patient education handout
Ciltacabtagene Autoleucel
infusions, intravenous
immunotherapy, adoptive
Product containing genetically modified T-cell (product)
Receptors, Chimeric Antigen
Cytokine Release Syndrome
continuity of patient care
Ciltacabtagene Autoleucel
neurotoxicity syndromes
drug compounding
ciltacabtagene autoleucel

---
https://ansm.sante.fr/tableau-marr/apixaban
2023
false
false
false
France
French
guidelines for drug use
risk management
apixaban
administration, oral
apixaban
continuity of patient care
hemorrhage
Drug-Related side effects and adverse reactions
patient education handout

---
https://onco-occitanie.fr/reunions-regionales/leucemies-aigues-les-diapositives-sont-en-lignes/
2023
France
scientific and technical information
congresses
leukaemia
Acute leukemia
leukemia
group processes

---
https://www.ema.europa.eu/en/medicines/human/EPAR/ebvallo
2023
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
Tabelecleucel
Tabelecleucel
orphan drug production
adult
child
adolescent
EBV-Related Post-Transplant Lymphoproliferative Disorder
transplantation
lymphoproliferative disorders
injections, intravenous
epstein-barr virus infections
Antineoplastic Agents, Immunological
product surveillance, postmarketing
immunotherapy, adoptive
lymphocyte transfusion
pregnancy
breast feeding
drug evaluation, preclinical
t-lymphocytes
tabelecleucel

---
https://www.has-sante.fr/jcms/p_3407460/fr/scemblix-asciminib-leucemie-myeloide-chronique
2023
false
false
false
France
insurance, health, reimbursement
treatment outcome
asciminib
leukemia, myelogenous, chronic, bcr-abl positive
Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive
recurrence
T315I mutation
Refractory Chronic Myeloid Leukemia, BCR-ABL1 Positive
Recurrent Chronic Myeloid Leukemia, BCR-ABL1 Positive
administration, oral
antineoplastic agents
evaluation of the transparency committee
leukemia, myelogenous, chronic, bcr-abl positive
asciminib

---
https://www.has-sante.fr/jcms/p_3407522/fr/yescarta-axicabtagene-ciloleucel-lymphome-folliculaire
2023
false
false
false
France
lymphoma, follicular
treatment outcome
insurance, health, reimbursement
adult
Refractory Follicular Lymphoma
Recurrent Follicular Lymphoma
infusions, intravenous
axicabtagene ciloleucel
evaluation of the transparency committee
axicabtagene ciloleucel

---
https://www.academie-medecine.fr/resumes-des-presentations-de-la-seance-du-24-janvier-2023-la-leucemie-a-promyelocytes-une-aventure-franco-chinoise-shanghai-paris-un-modele-pour-le-traitement-cible-des/
2023
France
congresses
scientific and technical information
leukaemia
Meeting Abstract
granulocyte precursor cells
Leukemia
promyelocytes
leukemia

---
https://www.cochrane.org/fr/CD013600/HAEMATOL_le-plasma-provenant-du-sang-de-personnes-ayant-gueri-de-la-covid-19-est-il-un-traitement-efficace
2023
United Kingdom
review of literature
french abstract
disease
persons
Other treatments
blood
plasma
COVID-19

---
https://www.ema.europa.eu/en/medicines/human/EPAR/xenpozyme
2023
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
enzyme replacement therapy
drug approval
europe
olipudase alfa
olipudase alfa
infusions, intravenous
olipudase alfa
Niemann-Pick disease, type B
Niemann-Pick disease, type A
orphan drug production
product surveillance, postmarketing
child
adolescent
adult
pregnancy
breast feeding
drug interactions
drug evaluation, preclinical

---
http://medecinetropicale.free.fr/cours/maladie_rat.pdf
2023
France
educational course
Disease
Diseases
splenic diseases
splenic disorder, nos

---
https://www.health.belgium.be/fr/avis-9718-prolongation-de-lage-autorise-pour-le-don-de-sang
2023
Belgium
public health guidelines
age, nos
long
blood donor, nos
Blood Donation
blood donors

---
https://ansm.sante.fr/tableau-acces-derogatoire/tafasitamab-200-mg-poudre-pour-solution-a-diluer-pour-perfusion
2023
false
false
false
France
French
infusions, intravenous
tafasitamab
tafasitamab
drug information
adult
lymphoma, large B-Cell, diffuse

---
https://www.has-sante.fr/jcms/p_3395770/fr/keytruda-pembrolizumab-melanome-de-stade-iib-iic-ou-iii
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
adult
adolescent
Stage IIB Cutaneous Melanoma AJCC v6 and v7
Stage IIC Cutaneous Melanoma AJCC v6 and v7
melanoma
Stage III Cutaneous Melanoma AJCC v7
Advanced Cutaneous Melanoma
infusions, intravenous
Antineoplastic Agents, Immunological
evaluation of the transparency committee
melanoma
pembrolizumab

---
https://ansm.sante.fr/tableau-marr/luspatercept
2023
false
false
false
France
French
guidelines for drug use
risk management
luspatercept
luspatercept
luspatercept
injections, subcutaneous
hematinics
hematinics
pregnancy
breast feeding
continuity of patient care
patient education handout
checklist
Female of Childbearing Potential
product surveillance, postmarketing
contraception

---
https://www.has-sante.fr/jcms/p_3348751/fr/carvykti-ciltacabtagene-autoleucel-myelome-multiple
2023
false
false
false
France
Ciltacabtagene Autoleucel
Ciltacabtagene Autoleucel
treatment outcome
insurance, health, reimbursement
adult
recurrence
immunotherapy, adoptive
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
package leaflet
summary of product characteristics
Chimeric Antigen Receptor T-Cell Therapy
Recurrent Multiple Myeloma
Triple-Class Refractory Multiple Myeloma
ciltacabtagene autoleucel
evaluation of the transparency committee
multiple myeloma

---
https://ansm.sante.fr/tableau-marr/axicabtagene-ciloleucel
2023
false
false
false
France
French
risk management
axicabtagene ciloleucel
guidelines for drug use
axicabtagene ciloleucel
Drug-Related side effects and adverse reactions
Cytokine Release Syndrome
nervous system diseases
patient education handout
signs and symptoms
axicabtagene ciloleucel
infusions, intravenous
gene therapy

---
https://ansm.sante.fr/tableau-marr/brexucabtagene-autoleucel
2023
false
false
false
France
French
risk management
brexucabtagene autoleucel
genetic therapy
gene therapy
Cytokine Release Syndrome
signs and symptoms
guidelines for drug use
patient education handout
Drug-Related side effects and adverse reactions
nervous system diseases
brexucabtagene autoleucel
brexucabtagene autoleucel

---
https://ansm.sante.fr/tableau-acces-derogatoire/oxbryta-voxelotor
2023
false
false
false
France
French
risk management
voxelotor
voxelotor
administration, oral
hematologic agents
drug information
anemia, hemolytic
anemia, sickle cell

---
https://ansm.sante.fr/tableau-acces-derogatoire/velcade-1-mg-poudre-pour-solution-injectable
2023
false
false
false
France
French
drug information
Bortezomib
injections, intravenous
Immunoglobulin Light-chain Amyloidosis
Non-amyloid monoclonal immunoglobulin deposition disease

---
https://ansm.sante.fr/tableau-acces-derogatoire/xalkori
2023
false
false
false
France
French
drug information
administration, oral
Crizotinib
antineoplastic agents
protein kinase inhibitors
capsules
pharmaceutical solutions
child
infant
lymphoma, large-cell, anaplastic
Childhood Anaplastic Large Cell Lymphoma, ALK-Positive
crizotinib
MET Exon 14 Mutation
Locally Advanced Lung Non-Small Cell Carcinoma
adult
Metastatic Lung Non-Small Cell Carcinoma
carcinoma, non-small-cell lung
continuity of patient care

---
https://ansm.sante.fr/tableau-marr/darbepoetin-alfa
2023
false
false
false
France
French
risk management
Darbepoetin alfa
darbepoetin alfa
hematinics
self administration
Self-administration error
patients guideline
checklist
injections
guidelines for drug use

---
https://ansm.sante.fr/tableau-marr/eculizumab
2023
false
false
false
France
French
risk management
guidelines for drug use
eculizumab
eculizumab
continuity of patient care
drug monitoring
patient safety
sepsis
meningococcal infections
risk
vaccination
antibiotic prophylaxis
adult
child
infant
patients guideline
patient education handout

---
https://ansm.sante.fr/actualites/point-de-situation-des-approvisionnements-des-medicaments-derives-du-sang
2023
false
false
false
France
French
drug information
Blood-Derivative Drugs
Blood derivative product (product)
blood proteins

---
http://publications.msss.gouv.qc.ca/msss/document-000269/
2023
false
true
false
Canada
neonatal screening
neonatal screening
neonatal screening
neonatal screening
infant, newborn
blood specimen collection
guideline
neonatal screening

---
https://ansm.sante.fr/tableau-marr/emicizumab
2023
false
false
false
France
French
emicizumab
risk management
thromboembolism
hemorrhage
thrombotic microangiopathies
blood coagulation tests
risk
hemorrhage
hemophilia A
patients guideline
guidelines for drug use
handbooks
Drug-Related side effects and adverse reactions
injections, subcutaneous
emicizumab
antibodies, bispecific
antibodies, monoclonal, humanized

---
https://ansm.sante.fr/informations-de-securite/veyvondiv-vonicog-alfa-facteur-von-willebrand-humain-recombinant-poudre-et-solvant-pour-solution-injectable-mises-en-garde-sur-la-lecture-du-dosage-du-produit-et-sur-le-calcul-du-nombre-de-flacons-necessaires-vmedicament-sous-surveillance-ren
2023
false
false
false
France
French
product surveillance, postmarketing
drug information
Vonicog Alfa
recombinant proteins
von willebrand factor
injections, intravenous
hemorrhage
hemorrhage
adult
von willebrand diseases
blood loss, surgical
blood loss, surgical

---
https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/cartographie-optique-du-genome-diagnostic-et-stratification-pronostique-des-hemopathies-malignes.html
2023
Canada
technical report
genome mapping
chromosome mapping
hematologic diseases
Malignant hemopathy
hematologic neoplasms
genome, nos
Hematologic and hematopoietic diseases
Optics
no diagnosis
Hemopathies
diagnosis

---
https://www.has-sante.fr/jcms/p_3459825/fr/enjaymo-sutimlimab-maladie-des-agglutinines-froides
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
sutimlimab
adult
evaluation of the transparency committee
cold agglutinin disease
anemia, hemolytic, autoimmune
sutimlimab

---
https://www.has-sante.fr/jcms/p_3461141/fr/brukinsa-zanubrutinib-leucemie-lymphoide-chronique-llc
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
Loss of Chromosome 17p
TP53 Gene Mutation
adult
del(17p) Negative
TP53 Gene Mutation Negative
Refractory Chronic Lymphocytic Leukemia
administration, oral
zanubrutinib
protein kinase inhibitors
antineoplastic agents
evaluation of the transparency committee
zanubrutinib
leukemia, lymphocytic, chronic, B-Cell

---
https://ansm.sante.fr/tableau-marr/lisocabtagene-maraleucel
2023
false
false
false
France
French
guidelines for drug use
risk management
Lisocabtagene Maraleucel
Lisocabtagene Maraleucel
Product containing only lisocabtagene maraleucel in parenteral dose form (medicinal product form)
Cytokine Release Syndrome
continuity of patient care
gene therapy
immunotherapy, adoptive
signs and symptoms
nervous system diseases
patients guideline
lisocabtagene maraleucel

---
https://www.has-sante.fr/jcms/p_3463592/fr/breyanzi-lisocabtagene-maraleucel-lymphome-folliculaire-de-grade-3b-lf3b
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
lymphoma, large B-Cell, diffuse
High Grade B-Cell Lymphoma
adult
Primary Mediastinal Large B-Cell Lymphoma
immunotherapy, adoptive
gene therapy
infusions, intravenous
evaluation of the transparency committee
Grade 3b Follicular Lymphoma
Lisocabtagene Maraleucel
lymphoma, follicular

---
https://www.has-sante.fr/jcms/p_3463441/fr/tecvayli-teclistamab-myelome-multiple
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
Triple-Class Refractory Multiple Myeloma
Recurrent Multiple Myeloma
adult
Antineoplastic Agents, Immunological
bispecific monoclonal antibodies
teclistamab
evaluation of the transparency committee
multiple myeloma
Teclistamab

---
https://www.cochrane.org/fr/CD010872/LIVER_utilisation-dagents-base-de-fibrine-pour-reduire-les-pertes-sanguines-chez-les-adultes-subissant-une
2023
false
false
false
United Kingdom
review of literature
french abstract
Core Device
Nucleotide
Hepatic
Use
adulthood
GDC Therapeutic Agent Terminology
hemorrhage, nos
Pharmacologic Substance
Baseline Epoch
Protocol Agent
hepatophyta
base, nos
Core Specimen
Legal Adult
fibrin
Limburgish Language
Surgical Procedure
Base of the Prostate
Fibrin
general surgery
Overdenture
Baseline
adult
hemorrhage
operative procedure, nos
Dental Base
liver, nos
Surgical Procedure was Curative Therapy
Blood Loss
fibrin

---
Summary Safety Review - Keytruda (pembrolizumab) and Tecentriq (atezolizumab) - Assessing the Potential Risk of Aplastic Anemia
https://pmps.hpfb-dgpsa.ca/documents-d-examen/ressource/SSR1691503886633
2023
false
false
false
Canada
French
drug evaluation
Drug-Related side effects and adverse reactions
pembrolizumab
antibodies, monoclonal, humanized
atezolizumab
Antineoplastic Agents, Immunological
risk assessment
anemia, aplastic
Immune Checkpoint Inhibitors
canada
pharmacovigilance note

---
https://ansm.sante.fr/tableau-marr/eculizumab-1
2023
false
false
false
France
French
risk management
guidelines for drug use
eculizumab
eculizumab
continuity of patient care
Drug-Related side effects and adverse reactions
vaccination
patients guideline
Infections
sepsis
meningococcal infections

---
https://ansm.sante.fr/informations-de-securite/blenrep-belantamab-mafodotin-et-myelome-multiple-lema-recommande-de-ne-pas-renouveler-son-amm-conditionnelle-en-raison-dun-manque-de-preuve-defficacite
2023
false
false
false
France
French
drug information
treatment outcome
belantamab mafodotin

---
https://www.has-sante.fr/jcms/p_3465836/fr/breyanzi-lisocabtagene-maraleucel-lymphome-diffus-a-grandes-cellules-b-ldgcb-lymphome-de-haut-grade-a-cellules-b-lhgcb-lymphome-mediastinal-primitif-a-grandes-cellules-b-lmpgcb-et-lymphome-folliculaire-de-grade-3b-lf3b
2023
false
false
false
France
French
evaluation of the transparency committee
insurance, health, reimbursement
treatment outcome
lymphoma, large B-Cell, diffuse
lymphoma, follicular
mediastinal neoplasms
Grade 3b Follicular Lymphoma
Primary Mediastinal Large B-Cell Lymphoma
High Grade B-Cell Lymphoma
Antineoplastic Agents, Immunological
Lisocabtagene Maraleucel
gene therapy
adult
infusions, intravenous
lisocabtagene maraleucel

---
https://ansm.sante.fr/tableau-marr/epcoritamab
2023
false
false
false
France
French
risk management
bispecific monoclonal antibodies
Epcoritamab
patients guideline
Cytokine Release Syndrome
signs and symptoms
Immune Effector Cell Associated Neurotoxicity Syndrome
cell-associated neurotoxicity
drug information
epcoritamab

---
https://www.has-sante.fr/jcms/p_3466363/fr/flash-securite-patient-surveillance-biologique-des-anticoagulants-heparines-et-antivitamines-k-une-prise-de-sang-pour-eviter-une-perte-de-sang
2023
France
guideline
Biological
heparin
CASP8AP2 wt Allele
Enhance
tool, nos
Blood
antivitamins K
Heparin
anticoagulants
biology
has patient
vitamine K antagonist
professional practice
antivitamins K
anticoagulant, nos
Professional Practice
Improved
Biological Monitoring
Scientific Equipment
Biological Challenge Agent
Heparin Measurement
Blood Sample
Biological Son
Murine Blood
blood specimen collection
Biological or Textual Reference to Actual Test or Parameter
Biological Agent
Patient Monitoring
blood
Safety Monitoring
Tool
containment of biohazards
patient safety
heparin
Biology

---
https://ansm.sante.fr/actualites/decision-du-18-10-2023-fixant-le-seuil-du-stock-de-securite-destine-au-marche-national-prevue-a-larticle-r-5124-49-4-iii-du-csp-pour-le-mitm-breyanzi-1-1-70-x-106-cellules-ml-1-1-70-x-106-cellules-ml-dispersion-pour-perfusion
2023
false
false
false
France
French
drug information
Lisocabtagene Maraleucel

---
https://www.has-sante.fr/jcms/p_3467526/fr/tibsovo-ivosidenib-leucemie-aigue-myeloide-lam
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
administration, oral
antineoplastic agents
ivosidenib
antineoplastic combined chemotherapy protocols
adult
IDH1 NP_005887.2:p.R132X
acute myeloid leukaemia with an IDH1 R132 mutation
Azacitidine/Ivosidenib Regimen
azacitidine
evaluation of the transparency committee
ivosidenib
leukemia, myeloid, acute

---
https://www.has-sante.fr/jcms/p_3467532/fr/kymriah-tisagenlecleucel-lymphome-diffus-a-grande-cellules-b-ldgcb
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
Recurrent Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
infusions, intravenous
tisagenlecleucel
Antineoplastic Agents, Immunological
receptors, antigen, t-cell
Anti-CD19 CAR T Cells Preparation
evaluation of the transparency committee
lymphoma, large B-Cell, diffuse
tisagenlecleucel

---
https://www.has-sante.fr/jcms/p_3467529/fr/yescarta-axicabtagene-ciloleucel-lymphome-diffus-a-grandes-cellules-b-ldgcb-lymphome-mediastinal-primitif-a-grandes-cellules-b-lmpgcb
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
infusions, intravenous
axicabtagene ciloleucel
Recurrent Primary Mediastinal Large B-Cell Lymphoma
Refractory Primary Mediastinal Large B-Cell Lymphoma
mediastinal neoplasms
gene therapy
Antineoplastic Agents, Immunological
Refractory Diffuse Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
adult
Anti-CD19 CAR T Cells Preparation
evaluation of the transparency committee
axicabtagene ciloleucel
lymphoma, large B-Cell, diffuse

---
https://www.ema.europa.eu/en/medicines/human/EPAR/sprycel
2023
false
true
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
Dasatinib
Dasatinib
dasatinib
adult
adolescent
child
antineoplastic agents
antineoplastic agents
protein kinase inhibitors
protein kinase inhibitors
leukemia, myeloid, chronic-phase
leukemia, myeloid, accelerated phase
leukemia, myelogenous, chronic, bcr-abl positive
precursor cell lymphoblastic Leukemia-Lymphoma

---
https://www.has-sante.fr/jcms/p_3470651/fr/epi-sense-guided-coagulation-system
2023
France
health technology assessment
heart
Adverse Event Associated with Coagulation
Tissue Factor Pathway Inhibitor
Handbook
heart, nos
coagulants
Systemic Immunotherapy
tissues
Cardiac
TFPI wt Allele
Coagulation Process
Coagulation Process
Therapeutic Epinephrine
Drug Delivery System Category
Device System
Personal Protective Equipment
coagulant, nos
Tissue
Guide Device
Drug Delivery System
Echo-Planar Imaging

---
https://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr=1348
2023
France
scientific and technical information
screening
Biological
syphilis
biology
Blood
Screening Study
blood donor, nos
Biological or Textual Reference to Actual Test or Parameter
biology
Genetic Screening
Murine Blood
Eligibility Determination
Cancer Screening
Trial Screening
Syphilis
blood donors
mass screening
Site Screening
Blood Sample
Biological Son
Biological Agent
Substance Screening
syphilis, nos
Last Screening
Biological Challenge Agent
Human Cells, Tissues, and Cellular and Tissue-Based Products Screening
Biology

---
https://www.has-sante.fr/jcms/p_3471810/fr/blenrep-belantamab-mafodotin-myelome-multiple
2023
false
false
false
France
insurance, health, reimbursement
treatment outcome
belantamab mafodotin
infusions, intravenous
adult
Refractory Multiple Myeloma
evaluation of the transparency committee
belantamab mafodotin
multiple myeloma

---
https://www.has-sante.fr/jcms/p_3471703/fr/methoxsalene-g-l-pharma-methoxsalene-lymphome-cutane
2023
false
false
false
France
Solution for blood fraction modification
insurance, health, reimbursement
Palliative Therapy
Extracorporeal Circulation Route of Administration
photosensitizing agents
palliative care
adult
evaluation of the transparency committee
methoxsalen
lymphoma, T-cell, cutaneous

---
https://ansm.sante.fr/informations-de-securite/ferrostrane-0-68-pour-cent-sirop-feredetate-de-sodium-risque-derreur-medicamenteuse-chez-les-nourrissons-de-faible-poids
2023
false
false
false
France
French
pharmacovigilance note
ferric sodium edetate
infant
infant, low birth weight
medication errors

---
https://publications.msss.gouv.qc.ca/msss/document-000848/
2023
Canada
handbooks
GDC Consent Type Terminology
Destination
Guide Device
Derivation Expression
Plasma
Handbook
Mathematical Derivation
Derivative
shunt, nos
blood transfusion
emigration and immigration
Blood Product
physicians
Bypass
Derived Flag
transfusion of plasma
Transfusion Of Blood Products
Deriving
Derivation
Derivation
Blood Transfusion
plasma
Mathematical Derivation
Medication

---
https://www.has-sante.fr/jcms/p_3476374/fr/brukinsa-zanubrutinib-macroglobulinemie-de-waldenstrom-mw
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
Refractory Waldenstrom Macroglobulinemia
adult
zanubrutinib
administration, oral
hematologic agents
protein kinase inhibitors
antineoplastic agents
evaluation of the transparency committee
zanubrutinib
waldenstrom macroglobulinemia

---
https://www.has-sante.fr/jcms/p_3451087/fr/
2023
France
evaluation of the transparency committee
hematologic neoplasms
hematologic diseases
Tabelecleucel

---
https://www.sfed.org/wp-content/uploads/2023/05/Electro-coagilation-1f7.pdf
2023
France
patient education handout
No Information Available
hemostasis
hemostatic function, nos
Informative
Oprelvekin
argon, nos
Plasma Product
Hemostasis
plasma
Informed
argon
Batroxobin
achievement
Plasma

---
https://ansm.sante.fr/actualites/fibrinogene-humain-lansm-a-elabore-un-guide-pratique-pour-favoriser-le-bon-usage-des-produits-disponibles
2023
false
false
false
France
French
drug compounding
drug storage
guidelines for drug use
fibrinogen
human fibrinogen
Fibrinogen Human
Product containing only human fibrinogen (medicinal product)
fibrinogen

---
https://www.santepubliquefrance.fr/les-actualites/2023/acces-au-don-de-sang-des-hommes-ayant-des-rapports-sexuels-entre-hommes-bilan-de-l-allegement-des-criteres-en-avril-2020
2023
France
scientific and technical information
Criterion
Mende Language
Murine Blood
blood donors
Checkup
Blood Donation
sexual intercourse, nos
Donation
coitus
Nurse Administrator
ELL wt Allele
Diazooxonorleucine
Multiple Endocrine Neoplasia
April
Menogaril
Blood
Sexual Intercourse
Balance Sheet
IVE Regimen
Blood Sample
Man
men

---
https://www.has-sante.fr/jcms/p_3482424/fr/tibsovo-ivosidenib-cancer-voies-biliaires
2023
false
false
false
France
adult
treatment outcome
insurance, health, reimbursement
antineoplastic agents
administration, oral
Advanced Cholangiocarcinoma
Unresectable Cholangiocarcinoma
Metastatic Cholangiocarcinoma
evaluation of the transparency committee
biliary tract cancer
biliary tract neoplasms
ivosidenib

---
https://www.has-sante.fr/jcms/p_3482310/fr/octaplaslg-proteines-plasmatiques-humaines-groupe-ab-hematologie
2023
false
false
false
France
infusions, intravenous
powders
treatment outcome
insurance, health, reimbursement
blood substitutes and plasma protein fractions
emergency treatment
shock, hemorrhagic
Massive blood transfusion (procedure)
Product containing plasma protein (product)
evaluation of the transparency committee
blood proteins
plasma proteins

---
https://www.sfed.org/wp-content/uploads/2023/05/hpg-330477-61316-gestion_des_antiagregants_et_anticoagulants_en_endoscopie_document_sfed_2023_a_partir_des_recommandations_bsg_esge_2021_-318879-u-e1d.pdf
2023
France
practice guideline
anticoagulants
endoscopy
platelet aggregation inhibitors
Management Occupations
anticoagulant, nos
Anticoagulant Agent
Endoscopic Procedure
endoscopy, nos
Management

---
https://ressources-aura.fr/wp-content/uploads/2024/01/BPP-RECO-2312APLASIE.pdf
2023
France
guideline
Management Occupations
pediatrics
Pediatricians
Clavulanate Potassium
Management
Childhood-Onset Systemic Lupus Erythematosus
Pediatric
hematology
aplasia, nos
Agenesis
pediatrician
Pediatric

---
https://ressources-aura.fr/wp-content/uploads/2024/01/BPP-RECO-ACC-2312.pdf
2023
France
guideline
Household
Family Study
Child, Foster
pediatrics
Childhood-Onset Systemic Lupus Erythematosus
family
Clavulanate Potassium
Child Individual
health planning guidelines
Pediatricians
Pediatric
Pediatric
hematology
foster child
Child Relation
pediatrician
child

---
https://ressources-aura.fr/wp-content/uploads/2024/01/BPA-FT23-11-MYELOG.pdf
2023
France
guideline
myelogram, nos
bone marrow examination

---
https://www.has-sante.fr/jcms/p_3418585/fr/yescarta-axicabtagene-ciloleucel-lymphome-ldgcb-lhgcb
2023
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
insurance, health, reimbursement
treatment outcome
Recurrent High Grade B-Cell Lymphoma
lymphoma, large B-Cell, diffuse
Refractory High Grade B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
adult
infusions, intravenous
gene therapy
axicabtagene ciloleucel

---
https://www.has-sante.fr/jcms/p_3419164/fr/tecartus-brexucabtagene-autoleucel-cellules-auto-logues-cd3-transduites-anti-cd19-leucemie-aigue-lymphoblastique-lal
2023
false
false
false
France
insurance, health, reimbursement
treatment outcome
recurrence
adult
brexucabtagene autoleucel
infusions, intravenous
immunotherapy, adoptive
Recurrent B Acute Lymphoblastic Leukemia
Refractory B Acute Lymphoblastic Leukemia
evaluation of the transparency committee
brexucabtagene autoleucel
precursor b-cell lymphoblastic leukemia-lymphoma

---
https://www.has-sante.fr/jcms/p_3419396/fr/aspaveli-pegcetacoplan-hpn
2023
false
false
false
France
insurance, health, reimbursement
treatment outcome
adult
pegcetacoplan
paroxysmal nocturnal hemoglobinuria
infusions, subcutaneous
evaluation of the transparency committee
pegcetacoplan
hemoglobinuria, paroxysmal

---
https://www.has-sante.fr/jcms/p_3419173/fr/arixtra-fondaparinux-sodique-antithrombotique
2023
false
false
false
France
insurance, health, reimbursement
fondaparinux
evaluation of the transparency committee
fondaparinux sodium
fibrinolytic agents
Fondaparinux
arixtra
antithrombotic agents

---
https://www.has-sante.fr/jcms/p_3419176/fr/yescarta-axicabtagene-ciloleucel-lymphome-diffus-a-grandes-cellules-b-ldgcb-et-lymphome-de-haut-grade-a-cellules-b-lhgcb
2023
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
axicabtagene ciloleucel
axicabtagene ciloleucel
infusions, intravenous
Recurrent Diffuse Large B-Cell Lymphoma
lymphoma, large B-Cell, diffuse
Refractory Diffuse Large B-Cell Lymphoma
Recurrent High Grade B-Cell Lymphoma
Refractory High Grade B-Cell Lymphoma
adult

---
https://www.has-sante.fr/jcms/p_3419442/fr/ultomiris-ravulizumab-myasthenie-acquise-generalisee-mag
2023
false
false
false
France
ravulizumab
treatment outcome
insurance, health, reimbursement
Anti-acetylcholine receptor antibody positivity
Acetylcholine receptor antibody (substance)
drug therapy, combination
adult
infusions, intravenous
evaluation of the transparency committee
myasthenia gravis
ravulizumab
myasthenia gravis, generalized

---
https://www.has-sante.fr/jcms/p_3422332/fr/jakavi-ruxolitinib-maladie-du-greffon
2023
false
false
false
France
insurance, health, reimbursement
treatment outcome
adolescent
graft vs host disease
acute disease
chronic disease
Steroid Refractory Graft Versus Host Disease
ruxolitinib
drug resistance
Chronic Graft Versus Host Disease
Acute Graft Versus Host Disease
administration, oral
evaluation of the transparency committee
ruxolitinib

---
https://ansm.sante.fr/tableau-marr/caplacizumab
2023
false
false
false
France
French
popular works
risk management
continuity of patient care
hemorrhage
caplacizumab
caplacizumab

---
https://ansm.sante.fr/tableau-acces-derogatoire/jakavi-5-mg-comprime
2023
false
false
false
France
French
insurance, health, reimbursement
ruxolitinib phosphate
ruxolitinib
administration, oral
drug information
graft vs host disease
drug resistance
Steroid Refractory Graft Versus Host Disease
acute disease
chronic disease

---
http://cuen.fr/manuel3/spip.php?rubrique8
2023
false
false
false
France
educational course
French pre-residency program examination
acid-base equilibrium
acid-base equilibrium

---
https://sfap.org/system/files/plaquette_soin_de_bouche.pdf
2023
France
patient education handout
platelet
blood platelets
nursing
mouth

---
https://www.has-sante.fr/jcms/p_3424344/fr/tecvayli-teclistamab-myelome-multiple
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
Triple-Class Refractory Multiple Myeloma
adult
antibodies, monoclonal
Teclistamab
injections, subcutaneous
Antineoplastic Agents, Immunological
teclistamab
evaluation of the transparency committee
multiple myeloma

---
https://www.cpias-auvergnerhonealpes.fr/Doc_Reco/neonatologie/hemoculture-2023.pdf
2023
France
scientific and technical information
blood culture, nos
Blood Culture
infant, newborn
newborn, nos

---
https://www.cochrane.org/fr/CD010590/RENAL_la-securite-et-lefficacite-relatives-de-differents-medicaments-base-depoetine-dans-le-traitement-de
2023
United Kingdom
review of literature
french abstract
chronic renal failure syndrome, nos
anemia
Renal failure
pharmaceutical preparations
due to
anemia, nos
erythropoietin
Safety
renal insufficiency, chronic
Chronic renal failure
drug, nos
safety
efficiency
Anemia
base, nos
persons

---
https://www.cochrane.org/fr/CD012349/CF_strategies-pour-augmenter-lobservance-du-traitement-par-chelation-du-fer-chez-les-personnes
2023
United Kingdom
review of literature
french abstract
persons
chelated iron
β-Thalassemia
Treatment Compliance
α δ-Thalassemia
anemia, sickle cell
β δ-Thalassemia
thalassemia, nos
chelation therapy
iron
patient compliance
hemoglobin s disease
α-Thalassemia
alpha-Thalassemia
thalassemia
disease

---
https://ansm.sante.fr/tableau-marr/rituximab-3
2023
false
false
false
France
French
guidelines for drug use
patient education handout
Rituximab
Rituximab

---
https://www.academie-medecine.fr/les-implications-medicales-et-societales-des-progres-considerables-faits-dans-la-prise-en-charge-des-leucemies-chroniques/
2023
France
scientific and technical information
leukemia
leukaemia
Leukemia
patient care management

---
https://www.has-sante.fr/jcms/p_3426154/fr/enbrel-etanercept-psoriasis-en-plaques-chez-l-enfant-et-l-adolescent
2023
false
false
false
France
etanercept
-
evaluation of the transparency committee
child
Etanercept
psoriasis
adolescent

---
https://www.has-sante.fr/jcms/p_3427072/fr/calquence-acalabrutinib-leucemie-lymphoide-chronique-llc
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
del(17p) Negative
TP53 Gene Mutation Negative
adult
Acalabrutinib/Obinutuzumab Regimen
administration, oral
acalabrutinib
Loss of Chromosome 17p
TP53 Gene Mutation
evaluation of the transparency committee
acalabrutinib
leukemia, lymphocytic, chronic, B-Cell

---
https://www.has-sante.fr/jcms/p_3427549/fr/scemblix-asciminib-leucemie-myeloide-chronique
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
adult
Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive
Refractory Chronic Myeloid Leukemia, BCR-ABL1 Positive
administration, oral
Tyrosine Kinase Inhibitors
asciminib
evaluation of the transparency committee
leukemia, myelogenous, chronic, bcr-abl positive
asciminib

---
https://www.has-sante.fr/jcms/p_3428384/fr/xalkori-crizotinib-lymphome-t-anaplasique-a-grandes-cellules-lagc-pediatrie
2023
false
false
false
France
child
treatment outcome
insurance, health, reimbursement
antineoplastic agents
crizotinib
guidelines for drug use
administration, oral
Childhood Anaplastic Large Cell Lymphoma, ALK-Positive
recurrence
protein kinase inhibitors
evaluation of the transparency committee
lymphoma, large-cell, anaplastic
Crizotinib

---
https://ansm.sante.fr/tableau-marr/ravulizumab
2023
false
false
false
France
French
risk management
ravulizumab
ravulizumab
ravulizumab
infusions, intravenous
guidelines for drug use
patients guideline
continuity of patient care
meningococcal infections
sepsis
neisseria meningitidis
vaccination
antibiotic prophylaxis
meningococcal infections
sepsis
child
infant
hemoglobinuria, paroxysmal
Atypical Hemolytic Uremic Syndrome
myasthenia gravis, generalized

---
https://www.has-sante.fr/jcms/p_3431851/fr/xenpozyme-olipudase-alfa-deficit-en-sphingomyelinase-acide
2023
false
false
false
France
evaluation of the transparency committee
sphingomyelin/cholesterol lipidosis, nos
xenpozyme
acid, nos
olipudase alfa
niemann-pick diseases
olipudase alfa

---
https://www.has-sante.fr/jcms/p_3427913/fr/soliris-eculizumab-syndrome-hemolytique-et-uremique-atypique-shua
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
eculizumab
infusions, intravenous
adult
child
evaluation of the transparency committee
Atypical Hemolytic Uremic Syndrome
eculizumab

---
https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/pertinence-dajouter-les-variantes-hbs-e-hbe-e-et-hbe-b-thal-aux-cibles-primaires-du-test-de-depistage-neonatal-des-hemoglobinopathies.html
2023
Canada
public health guidelines
hemoglobinopathy, nos
hemoglobinopathies
principal
neonatal screening, nos
Hemoglobinopathy
neonatal screening
dermatomyositis

---
https://www.has-sante.fr/jcms/p_3433398/fr/ultomiris-ravulizumab-syndrome-hemolytique-et-uremique-atypique-shua
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
infusions, intravenous
ravulizumab
complement C5
complement inactivating agents
evaluation of the transparency committee
ravulizumab
Atypical Hemolytic Uremic Syndrome

---
https://www.has-sante.fr/jcms/p_3434604/fr/brukinsa-zanubrutinib-leucemie-lymphoide-chronique
2023
false
false
false
France
evaluation of the transparency committee
zanubrutinib
leukemia, lymphoid
leukaemia
zanubrutinib
Brukinsa
leukemia, lymphocytic, chronic, B-Cell
Chronic lymphocytic leukemia
chronic lymphocytic leukemia

---
https://www.has-sante.fr/jcms/p_3434163/fr/lonquex-lipegfilgrastim-facteur-de-croissance-granulocytaire
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
lipegfilgrastim
adult
child
adolescent
Chemotherapy-Induced febrile neutropenia
Chemotherapy-Induced febrile neutropenia
evaluation of the transparency committee
granulocyte colony-stimulating factor
lipegfilgrastim

---
http://nuxeo.edel.univ-poitiers.fr/nuxeo/site/esupversions/dda32ff9-7ea7-43de-9b76-dfa1836a68e4
2023
France
Physicians
activir
aged
case management
disease
has patient
patient care
role
activator appliances
principal
physician's role
medicine
physicians
hematology
primary health care
physicians, primary care
antineoplastic agents
Hematology

---
https://www.yearbook-ers.jle.com/e-docs/champ_magnetique_50hz_et_leucemies_de_lenfant_une_nouvelle_meta_analyse_322289/yb_breve.phtml
2022
false
false
false
France
journal article
magnetic fields
child
leukemia
Meta-Analysis

---
https://www.yearbook-ers.jle.com/e-docs/exposition_prenatale_aux_substances_per_et_poly_fluoroalkylees_methylation_de_ladn_dans_le_sang_du_cordon_et_indicateurs_cardiometaboliques_chez_le_nouveau_ne_letude_healthy_start__322285/yb_breve.phtml
2022
false
false
false
France
journal article
Exhibition
dna methylation
cord blood
fetal blood
indicators and reagents
data collection
infant, newborn
indicators

---
https://ansm.sante.fr/tableau-acces-derogatoire/thalidomide-bms-50-mg-gelule
2022
false
false
false
France
French
guidelines for drug use
continuity of patient care
thalidomide
administration, oral
Jessner lymphocytic infiltration of the skin
lupus erythematosus, cutaneous
stomatitis, aphthous
Immune complex reaction co-occurrent and due to multibacillary leprosy (disorder)
crohn disease
erythema multiforme
Erythema multiforme major

---
https://www.ineris.fr/sites/ineris.fr/files/contribution/Plaquette_ERS_v5.pdf
2022
France
handbooks
emission, nos
health status
blood platelets
platelet
health status indicators
health risk appraisal
filing
environment

---
https://www.has-sante.fr/jcms/p_3348600/fr/oxbryta-voxelotor-carcinome-urothelial-anemie-hemolytique
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
voxelotor
drug therapy, combination
anemia, sickle cell
administration, oral
voxelotor
hydroxyurea
adult
adolescent
evaluation of the transparency committee
voxelotor

---
https://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr=1227
2022
France
scientific and technical information
blood cells
waiting lists
"u" lymphocyte
Viruses
tissues
risk
virus, nos
organ part
Blood cell
organizations
mail
west nile virus
Drives
Virus
postal service
Blood cells

---
https://www.paediatrieschweiz.ch/fr/derriere-une-thrombocytopenie/
2022
Switzerland
journal article
sarcoidosis, nos
recurrent
thrombocytopenia
increased body temperature
Fever
fever
thrombocytopenia, nos
Sarcoidosis
Recidivism
fever
posterior
Lymphadenopathy
sarcoidosis
immunologic deficiency syndromes
occult
enlargement of lymph nodes, nos

---
https://www.paediatrieschweiz.ch/fr/oesophagite-a-eosinophiles-update-2022/
2022
Switzerland
journal article
Esophagitis
eosinophilic esophagitis
eosinophil
esophagitis, nos
Eosinophilia
eosinophilia, nos

---
https://www.has-sante.fr/jcms/p_3262259/fr/kymriah-tisagenlecleucel-ldgcb
2022
France
evaluation of the transparency committee
KYMRIAH
lymphoma, large B-Cell, diffuse
tisagenlecleucel
tisagenlecleucel

---
https://www.afsos.org/wp-content/uploads/2022/06/AFSOS-Referentiel-me%CC%81ditation-de-pleine-conscience-02-06.pdf
2022
France
guideline
Hematology
hematology
mindfulness
consciousness, nos
meditation

---
https://www.afsos.org/wp-content/uploads/2022/06/Thrombopenie-et-Cancer-AFSOS-02-06.pdf
2022
France
guideline
cancer
Cancer
Thrombocytopenia
thrombocytopenia, nos
neoplasms
thrombocytopenia
neoplasm, malignant

---
https://www.ema.europa.eu/en/medicines/human/EPAR/oxbryta
2022
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
voxelotor
voxelotor
voxelotor
orphan drug production
anemia, sickle cell
Oxbryta
drug approval
europe
adolescent
adult
administration, oral
aged
hematologic agents
hematologic agents
product surveillance, postmarketing
pregnancy
breast feeding
drug therapy, combination
drug interactions
hemoglobin, sickle
drug evaluation, preclinical

---
https://www.ema.europa.eu/en/medicines/human/EPAR/stimufend
2022
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
pegfilgrastim
pegfilgrastim
pegfilgrastim
biosimilar pharmaceuticals
drug approval
europe
Chemotherapy induced neutropenia
Chemotherapy-Induced febrile neutropenia
injections, subcutaneous
pregnancy
breast feeding
drug interactions
product surveillance, postmarketing
Product containing only pegfilgrastim in parenteral dose form (medicinal product form)
drug evaluation, preclinical

---
https://www.ema.europa.eu/en/medicines/human/EPAR/breyanzi
2022
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Lisocabtagene Maraleucel
Lisocabtagene Maraleucel
gene therapy
drug approval
europe
adult
lymphoma, large B-Cell, diffuse
Primary Mediastinal Large B-Cell Lymphoma
Grade 3b Follicular Lymphoma
lymphoma, follicular
infusions, intravenous
Cytokine Release Syndrome
pregnancy
breast feeding
drug interactions
Receptors, Chimeric Antigen
product surveillance, postmarketing
Anti-CD19 CAR T Cells Preparation
aged
continuity of patient care
immunotherapy, adoptive
drug evaluation, preclinical
mediastinal neoplasms
lisocabtagene maraleucel

---
https://www.ema.europa.eu/en/medicines/human/EPAR/zolsketil-pegylated-liposomal
2022
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
doxorubicin
doxorubicin
doxorubicin
antibiotics, antineoplastic
antibiotics, antineoplastic
liposomal doxorubicin
liposomal doxorubicin
Pegylated Liposomal Doxorubicin Hydrochloride
drug approval
europe
adult
breast neoplasms
Metastatic Breast Carcinoma
neoplasm metastasis
ovarian neoplasms
Advanced Ovarian Carcinoma
Platinum-Refractory Ovarian Carcinoma
multiple myeloma
sarcoma, kaposi
AIDS-related kaposi sarcoma
aids-related opportunistic infections
infusions, intravenous
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
antineoplastic combined chemotherapy protocols
Bevacizumab/Liposomal Doxorubicin Regimen

---
https://www.ema.europa.eu/en/medicines/human/EPAR/carvykti
2022
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Ciltacabtagene Autoleucel
Ciltacabtagene Autoleucel
orphan drug production
multiple myeloma
Recurrent Multiple Myeloma
Refractory Multiple Myeloma
adult
infusions, intravenous
continuity of patient care
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
immunotherapy, adoptive
drug evaluation, preclinical
ciltacabtagene autoleucel

---
https://www.has-sante.fr/jcms/p_3349491/fr/blincyto-blinatumomab
2022
false
false
false
France
French
treatment outcome
insurance, health, reimbursement
adult
evaluation of the transparency committee
recurrence
precursor cell lymphoblastic Leukemia-Lymphoma
Adult B Acute Lymphoblastic Leukemia
blinatumomab
blinatumomab
infusions, intravenous
Recurrent B Acute Lymphoblastic Leukemia
Refractory B Acute Lymphoblastic Leukemia
antineoplastic agents

---
https://www.has-sante.fr/jcms/p_3348719/fr/kymriah-tisagenlecleucel-lymphome-folliculaire
2022
France
evaluation of the transparency committee
tisagenlecleucel
malignant lymphoma, nos
lymphoma, follicular
KYMRIAH
Follicular lymphoma
tisagenlecleucel

---
https://www.minerva-ebp.be/FR/Article/2273
2022
Belgium
critical appraisal or critical reading
telephone switchboard operator
risk assessment
risks and benefits
asthenia
atrial fibrillation
due to
anticoagulants
leadership
atrial fibrillation
has patient
warfarin
patients
anticoagulant, nos
disease
warfarin
reference standards
guideline
Atrial fibrillation
oral anticoagulants

---
https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/mise-a-jour-du-guide-dusage-optimal-sur-les-infections-transmissibles-sexuellement-et-par-le-sang-infection-confirmee-a-mycoplasma-genitalium.html
2022
Canada
technical report
Infections
Handbook
infectious disease, nos
sexually transmitted diseases
Infectious disease
blood

---
https://www.santepubliquefrance.fr/les-actualites/2022/syndrome-hemolytique-et-uremique-pediatrique-les-mesures-de-prevention-face-aux-risques-de-l-ete
2022
France
popular works
weights and measures
risk
Pediatricians
hemolytic-uremic syndrome
hemolytic uremic syndrome, nos
face
pediatrician
pediatrics
Hemolytic uremic syndrome
measures

---
https://www.has-sante.fr/jcms/p_3352191/fr/methoxsalene-macopharm-methoxsalene-lymphome-cutane
2022
false
false
false
France
palliative care
adult
lymphoma, T-cell, cutaneous
treatment outcome
insurance, health, reimbursement
Extracorporeal Circulation Route of Administration
evaluation of the transparency committee
methoxsalen

---
https://www.has-sante.fr/jcms/p_3358127/fr/ultomiris-ravulizumab-hemoglobinurie-paroxystique-nocturne-chez-les-patients-pediatriques
2022
false
false
false
France
ravulizumab
insurance, health, reimbursement
treatment outcome
infusions, intravenous
child
evaluation of the transparency committee
hemoglobinuria, paroxysmal
ravulizumab
paroxysmal nocturnal hemoglobinuria

---
https://www.has-sante.fr/jcms/p_3358109/fr/octagam-immunoglobuline-humaine-normale-dermatomyosite
2022
false
false
false
France
immunoglobulins, normal human, for intravascular adm.
insurance, health, reimbursement
treatment outcome
infusions, intravenous
immunologic factors
adult
drug therapy, combination
evaluation of the transparency committee
dermatomyositis
immunoglobulins, intravenous

---
https://www.has-sante.fr/jcms/p_3359507/fr/xalkori-crizotinib-lymphome-t-anaplasique-a-grandes-cellules-lagc
https://www.has-sante.fr/jcms/p_3359522/fr/decision-n2022-0280/dc/sem-du-21-juillet-2022-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-xalkori
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
crizotinib
administration, oral
protein kinase inhibitors
child
adolescent
recurrence
Childhood Anaplastic Large Cell Lymphoma, ALK-Positive
Recurrent Childhood Anaplastic Large Cell Lymphoma
Refractory Anaplastic Large Cell Lymphoma
ALK Fusion Protein Expression
guidelines for drug use
evaluation of the transparency committee
Crizotinib
lymphoma, large-cell, anaplastic

---
https://www.has-sante.fr/jcms/p_3359432/fr/ayvakyt-avapritinib-mastocytose-systemique-agressive-asm
https://www.has-sante.fr/jcms/p_3359458/fr/decision-n2022-0278/dc/sem-du-21-juillet-2022-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-ayvakyt
2022
false
false
false
France
adult
Systemic Mastocytosis with an Associated Myeloid Neoplasm
protein kinase inhibitors
avapritinib
leukemia, mast-cell
treatment outcome
insurance, health, reimbursement
guidelines for drug use
continuity of patient care
administration, oral
evaluation of the transparency committee
avapritinib
aggressive systemic mastocytosis
mastocytosis, systemic

---
https://www.has-sante.fr/jcms/p_3358972/fr/yescarta-axicabtagene-ciloleucel-lymphome-diffus-a-grandes-cellules-b
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
Refractory Diffuse Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
infusions, intravenous
axicabtagene ciloleucel
guidelines for drug use
adult
evaluation of the transparency committee
axicabtagene ciloleucel
lymphoma, large B-Cell, diffuse

---
https://www.has-sante.fr/jcms/p_3358913/fr/jakavi-ruxolitinib-maladie-du-greffon
https://www.has-sante.fr/jcms/p_3358954/fr/decision-n2022-0214/dc/sem-du-30-juin-2022-du-college-de-la-haute-autorite-de-sante-portant-delegation-en-matiere-d-autorisation-d-acces-precoce-de-la-specialite-jakavi
2022
false
false
false
France
graft vs host disease
treatment outcome
insurance, health, reimbursement
adult
adolescent
administration, oral
evaluation of the transparency committee
ruxolitinib

---
https://ansm.sante.fr/informations-de-securite/thrombolytiques-conduite-a-tenir-dans-un-contexte-de-tensions-dapprovisionnement
2022
false
false
false
France
French
drug information
fibrinolytic agents
guideline

---
https://ansm.sante.fr/tableau-marr/blinatumomab
2022
false
false
false
France
French
risk management
medication errors
blinatumomab
continuity of patient care
guidelines for drug use
guideline
patient education handout
nervous system diseases
Neurotoxicity (disorder)
antineoplastic agents
blinatumomab
infusions, intravenous

---
https://ansm.sante.fr/actualites/decision-du-16-08-2022-renouvellement-du-cadre-de-prescription-compassionnelle-de-thalidomide-bms-50-mg-gelule-et-des-medicaments-qui-appartiennent-au-meme-groupe-generique
https://ansm.sante.fr/tableau-acces-derogatoire/thalidomide-bms-50-mg-gelule
2022
false
false
false
France
French
thalidomide
legislation, drug
drug information
administration, oral

---
https://www.has-sante.fr/jcms/p_3361547/fr/civaron-sodium-citrate-de-anticoagulation-regionale-au-citrate-arc
2022
false
false
false
France
Citrate anticoagulation solution (physical object)
Extracorporeal Circulation Route of Administration
renal dialysis
clotting in the extracorporeal circuit during haemodialysis
evaluation of the transparency committee
anticoagulants
Sodium Citrate

---
https://www.has-sante.fr/jcms/p_3361556/fr/oxbryta-voxelotor-anemie-hemolytique-severe
2022
false
false
false
France
insurance, health, reimbursement
treatment outcome
voxelotor
administration, oral
hematologic agents
adult
adolescent
drug therapy, combination
hydroxyurea
evaluation of the transparency committee
Oxbryta
voxelotor
anemia, sickle cell

---
https://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr=1139
2022
France
COVID-19
public health guidelines
patient selection
blood donor, nos
blood chemical analysis
risk assessment
evaluation studies as topic
blood test
donor selection
Drives
sexual behavior, nos
blood donors
selection criteria
unsafe sex
safe sex
infectious agent, nos

---
Nous contacter.
02/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.